Navigation Links
Cardiff scientists study acute infection in end-stage kidney disease patients
Date:11/13/2008

A new research study underway at Cardiff University could see a decrease in the rates of treatment failure among patients with end-stage kidney disease.

Experts in the Infection, Immunity and Inflammation Interdisciplinary Research Group at the School of Medicine have secured more than 230,000 ($375,000) from the 'Renal Discoveries - The Baxter Extramural Grant' program, to investigate the potential to safeguard susceptible patients against serious problems caused by bacterial infections.

Each year Baxter Healthcare Corporation awards the Baxter Extramural Grant for innovation, exploration and application of research to advance the knowledge of renal conditions and its treatment. With only four grants awarded world-wide each year, Cardiff University is the sole recipient of the funding for the Europe/Middle East/Africa and Russia region.

Bacterial infection among patients with end-stage kidney disease is one of the major reasons for treatment failure and mortality, particularly among patients receiving peritoneal dialysis, the form of dialysis that cleans the blood inside the body through the peritoneum.

Now, thanks to the three year funding, the multidisciplinary team sponsored by Professor of Medicine John Williams, at Cardiff University will begin studying the consequence of infection by bacteria in order to understand, and in the future better regulate, a patient's immune response to infections. The team brings together clinicians and researchers at the Peritoneal Dialysis Unit, the Institute of Nephrology, and the Department of Medical Biochemistry and Immunology.

Dr Matthias Eberl, principal investigator at the Department of Medical Biochemistry and Immunology, said: "Although peritoneal dialysis has a number of advantages such as independence from hospital and improved quality of life, infections still pose major risks to the patient. As treatment failure in these patients correlates directly with the severity of the inflammatory response and antibiotic resistance is becoming a significant problem, we need to understand why some patients are more prone to treatment failure than others."

The Baxter grant also includes a three-year visiting fellowship for a peritoneal dialysis specialist from Chang Gung Memorial Hospital in Taiwan. Dr Chan-Yu Lin will conduct his PhD studies at Cardiff University on peritoneal dialysis-related infections and receive training in early treatment of inflammation, microbiological diagnosis, and analysis of patient samples in the laboratory.

Dr Eberl said: "We are studying the immune response in peritoneal dialysis patients during episodes of bacterial peritonitis to improve current ways of infection prevention and therapy. However, the scope of our work is much wider in the context of infectious and inflammatory disease in other organs and in sepsis."

Earlier this year Dr Eberl's team together with Professor Nicholas Topley at the Department of Medical Biochemistry and Immunology were awarded a Welsh Assembly Government /Medical Research Council Health Research Partnership Award from the Wales Office of Research and Development for their work on peritoneal dialysis-related infection.


'/>"/>

Contact: Dr Matthias Eberl
eberlm@cardiff.ac.uk
Cardiff University
Source:Eurekalert

Related medicine news :

1. Scientists Unravel Mystery of Tamoxifen Resistance
2. Freezing Ovaries Preserves Fertility, Scientists Report
3. TSODs Frank Whyte Provides Negotiation Skills Training to NIH Scientists
4. Scientists Debate Dietary Supplements and Cancer Risk at AICR Conference
5. Penn scientists show how body determines optimal amount of germ-fighting B cells
6. Penn scientists map molecular regulation of fat-cell genetics
7. Scientists Make Clones of Mice Dead 16 Years
8. Anti-VEGF drugs for retinal diseases could have serious side effects, scientists caution
9. Anti-VEGF Drugs for Retinal Diseases Could Have Serious Side Effects, Scientists Caution
10. Scientists Develop New Strategy to Fight Obesity
11. Scientists Spot 4 New Alzheimers Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology: